This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pfizer (PFE), Dexcom (DXCM) and Glaukos (GKOS)

Tipranks - Tipranks - Tue Jun 9, 4:28AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE), Dexcom (DXCM) and Glaukos (GKOS).

Introducing TipRanks MCP for Agents

Pfizer (PFE)

In a report issued on June 5, Mohit Bansal from Wells Fargo maintained a Hold rating on Pfizer, with a price target of $28.00. The company’s shares closed last Friday at $26.04.

According to TipRanks.com, Bansal is a 5-star analyst with an average return of 9.7% and a 58.1% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., BioMarin Pharmaceutical, and Vertex Pharmaceuticals. ;'>

Currently, the analyst consensus on Pfizer is a Hold with an average price target of $29.17, which is a 12.8% upside from current levels. In a report issued on May 26, Citi also maintained a Hold rating on the stock with a $27.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Dexcom (DXCM)

In a report released yesterday, Travis Steed from Bank of America Securities maintained a Buy rating on Dexcom, with a price target of $80.00. The company’s shares closed last Friday at $72.86, close to its 52-week low of $62.34.

According to TipRanks.com, Steed is a 3-star analyst with an average return of 0.7% and a 48.8% success rate. Steed covers the Healthcare sector, focusing on stocks such as Kestra Medical Technologies Ltd., Bausch + Lomb Corporation, and Inspire Medical Systems. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dexcom with a $80.68 average price target, a 9.8% upside from current levels. In a report issued on May 29, TipRanks – Anthropic also upgraded the stock to Buy with a $77.00 price target.

Glaukos (GKOS)

In a report issued on June 5, Larry Biegelsen from Wells Fargo reiterated a Buy rating on Glaukos, with a price target of $138.00. The company’s shares closed last Friday at $125.00.

According to TipRanks.com, Biegelsen is a 3-star analyst with an average return of 1.2% and a 48.6% success rate. Biegelsen covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Glaukos with a $153.00 average price target, which is a 24.7% upside from current levels. In a report issued on May 22, Truist Financial also maintained a Buy rating on the stock.

Read More on PFE:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).